Dengue Vaccine Strategy in Children Aged 9 to 17 Years in the French Caribbean
Recruiting
Observational Study
Dengue
Vaccination
Seroprevalence
Infectious Disease
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 9 – 17
- Sex
- Any
- Study type
- Observational
- Participants needed
- 590 (estimated)
- Sponsor
- University Hospital Center of Martinique · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Dengue fever, an arbovirus transmitted by the Aedes mosquito, is a public health problem in all tropical and subtropical regions of the world. There is currently no antiviral treatment and vector control has shown its limits. The 2018 European marketing authorization of the tetravalent chimeric yellow fever / dengue vaccine (Dengvaxia®) is a major step forward in the fight against the disease. Den…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
CHILDREN
Inclusion Criteria for children:
* Any child aged 9 to 17 years presenting to one of the hospital departments participating in the study at the University Hospitals of Martinique or Guadeloupe
* Need to take a blood sample or place a peripheral venous line for the management of the child
…
Contacts